This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jimenez, E.
Right arrow Articles by Gargallo-Viola, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jimenez, E.
Right arrow Articles by Gargallo-Viola, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2648-2650, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2648-2650.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Therapeutic Efficacies of GW471552 and GW471558, Two New Azasordarin Derivatives, against Pneumocystosis in Two Immunosuppressed-Rat Models

Elena Jimenez,1 Antonio Martínez,1 El Moukhtar Aliouat,2 Jesus Caballero,3 Eduardo Dei-Cas,4 and Domingo Gargallo-Viola1*

GlaxoSmithKline, Madrid,1 Laboratorios Hipra, Girona, Spain,3 Laboratory of Parasitology, School of Pharmacy, Lille-II University,2 Lille-CHRU, Ecology of Parasitism, Institute Pasteur of Lille, Lille, France4

Received 31 January 2002/ Returned for modification 11 March 2002/ Accepted 14 May 2002

Two new azasordarins, GW471552 and GW471558, were studied in vivo for treatment of Pneumocystis carinii pneumonia. In the Wistar rat spontaneous pneumonia model, both azasordarins significantly reduced the number of P. carinii cysts per gram of lung homogenate when administered at 1 mg/kg of body weight twice a day for 10 days. In a nude rat inoculation model, both compounds showed therapeutic efficacy at 0.25 mg/kg twice a day for 10 days.

* Corresponding author. Mailing address: GlaxoSmithKline, Parque Tecnológico de Madrid, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain. Phone: 34.91.80.70.481. Fax: 34.91.80.70.595. E-mail: dgv28867{at}gsk.com.

Antimicrobial Agents and Chemotherapy, August 2002, p. 2648-2650, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2648-2650.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodriguez, M., Fishman, J. A. (2004). Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients. Clin. Microbiol. Rev. 17: 770-782 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»